Entopsis , Inc. – FDA 483, Dec 6, 2022
An FDA inspection of Entopsis, Inc. in Medley, FL, revealed significant deficiencies across its quality system. The firm failed to validate critical manufacturing processes, software, and equipment, indicating a broad lack of control over its PCRopsis product production. Additionally, inadequate procedures for acceptance activities, complaint handling, supplier qualification, and document control were observed, highlighting systemic issues in maintaining compliance with regulatory requirements.
ID · 71cb54cf-ddd9-42a3-8e87-e36337d100ef
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.